Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 05, 2023 08:00 ET | Source: iBio, Inc.

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of...
November 27, 2023 17:20 ET | Source: iBio, Inc.

iBio Announces Reverse Stock Split

BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of...
November 01, 2023 08:24 ET | Source: iBio, Inc.

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action - BRYAN, Texas and SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- iBio,...
October 10, 2023 08:00 ET | Source: iBio, Inc.

iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics

- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries - BRYAN, Texas...
October 02, 2023 06:45 ET | Source: iBio, Inc.

iBio Explains Recent Filing of Registration Statement

BRYAN, Texas and SAN DIEGO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- In response to investor inquiries received about the post-effective amendment to its Form S-3 on Form S-1 (the “Post-Effective...
September 27, 2023 16:19 ET | Source: iBio, Inc.

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

BRYAN, Texas and SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the...
September 21, 2023 16:05 ET | Source: iBio, Inc.

iBio Announces Amendment to Credit Agreement with Woodforest

– Extends maturity date to December 31, 2023 –– Allows time to close pending sale of CDMO facility –BRYAN, Texas and SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or...
August 14, 2023 16:15 ET | Source: iBio, Inc.

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets – BRYAN, Texas and SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)...
June 27, 2023 08:00 ET | Source: iBio, Inc.

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth

– Board appointments solidify management team to lead iBio’s AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the...
June 12, 2023 16:15 ET | Source: iBio, Inc.

iBio Forges Research Collaboration with the National Institutes of Health

– NIH to evaluate iBio’s patented AI-driven epitope steering platform for Lassa fever vaccine development – BRYAN, Texas and SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)...